Participate in migraines Clinical Trial Today

Active and recruiting trials

  • The REMODEL-2 Study is a Phase 3b study using remibrutinib for those with Relapsing Multiple Sclerosis. Approximately 800 participants are expected to take part in North America and Europe.

    For more information, please visit clinicaltrials.gov.

    If you are interested in participating, please contact Yousri YBenchaar@gengepartners.com

  • The FREVIVA Study is a Phase 3 study using frexalimab for those with Nonrelapsing Secondary Progressive Multiple Sclerosis. Approximately 858 participants are expected to take part in North America and Europe.

    For more information, please visit clinicaltrials.gov.

    If you are interested in participating, please contact Yousri YBenchaar@gengepartners.com

Active but not recruiting trials

  • This study is closed for recruitment

    The Eye-Tracking Neurological Assessment for Multiple Sclerosis (ETNA™-MS) is a software as a medical device (SaMD), Class II, intended to administer a non-invasive test that allows clinicians to track eye-movement metrics in adult patients and to provide an Expanded Disability Status Scale (EDSS) score in the range between 1.0 and 7.0 and a Symbol Digit Modalities Test (SDMT) score –a measure of cognitive processing speed– for use in tracking disease progression and cognitive function in MS patients. 

Upcoming trials

  • More info to come

If you would like to hear about more about our current or upcoming neurological clinical trials in Montreal please contact us at: info@gengepartners.com

“If we’re not in the beginning for rare disease, we may simply be too late for our patients to get the benefit of these new therapies.”

-Angela Genge

  • Our mission

    To improve patient health and well-being by conducting cutting-edge clinical research. We strive to foster a culture of innovation, collaboration, and excellence in all aspects of our research, and to contribute to the global effort to improve healthcare for all.

  • Our vision

    To be a leading force in advancing medical knowledge and improving patient care through innovative and ethical clinical research

  • Our future

    Genge Partners will continue to be at the forefront of clinical research, utilizing the latest technologies and methodologies to bring new treatments and therapies to patients in need. Our commitment to patient safety, scientific rigor, and ethical conduct will remain steadfast, as we work to improve healthcare for all and make a lasting impact on the field of medicine.

Our facility:

Genge Partners @ Glen
5100 Boul. de Maisonneuve Ouest, 6th floor
Montreal, QC H4A 3TA

 

© 2022 Genge Partners Inc. All rights reserved | Confidentiality policy